Zymeworks Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Zymeworks Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ZYME
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001937653
Board of directors
-
Alessandra Cesano · DirectorSince 2024
-
Brian N. Cherry · DirectorSince 2026
-
Carlos Campoy · DirectorSince 2023
-
Derek John Michael Miller · DirectorSince 2023
-
Gregory Austin Ciongoli · DirectorSince 2025
-
Hollings Renton · DirectorSince 2023
-
Kelvin Neu · DirectorSince 2023
-
Kenneth Galbraith · Director · Chair & CEOSince 2023
-
Kenneth J. Hillan · DirectorSince 2023
-
Nancy Davidson · DirectorSince 2023
-
Neil Gallagher · DirectorSince 2024
-
Oleg Nodelman · DirectorSince 2025
-
Robert E. Landry · DirectorSince 2025
-
Scott Platshon · DirectorSince 2024
-
Susan Mahony · DirectorSince 2023
-
Troy Cox · DirectorSince 2023
Chief executives
Kenneth Galbraith
· Chair & CEO
Dates unknown
Board connections
9 of this board's directors also sit on 15 other boards.
- via Hollings Renton and Oleg Nodelman
- via Brian N. Cherry and Gregory Austin Ciongoli
- via Oleg Nodelman
- via Susan Mahony
- via Susan Mahony
- via Robert E. Landry
- via Neil Gallagher
- via Gregory Austin Ciongoli
- via Troy Cox
- via Oleg Nodelman
- via Alessandra Cesano
- via Gregory Austin Ciongoli
- via Troy Cox
- via Troy Cox
- via Alessandra Cesano
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,673,716
- 10 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 6, 2026 | Hollywood Mark Officer (EVP & Chief Operating Officer) | Grant or award | +939 | $22.22 | $20,865 |
| Jan 12, 2026 | Hollywood Mark Officer (EVP & Chief Operating Officer) | Option exercise | +17,666 | — | — |
| Jan 12, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Option exercise | +17,666 | — | — |
| Jan 12, 2026 | Moore Paul Andrew Officer (Chief Scientific Officer) | Option exercise | +17,666 | — | — |
| Jan 12, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Option exercise | +64,000 | — | — |
| Jan 12, 2026 | Hollywood Mark Officer (EVP & Chief Operating Officer) | Open-market sale | −6,120 | $22.67 | $138,740 |
| Jan 12, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Open-market sale | −9,310 | $22.67 | $211,058 |
| Jan 12, 2026 | Moore Paul Andrew Officer (Chief Scientific Officer) | Open-market sale | −9,560 | $22.67 | $216,725 |
| Jan 12, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Open-market sale | −30,424 | $22.67 | $689,712 |
| Jan 6, 2026 | Leone D. Patterson Officer (EVP, Chief Bus & Fin Officer) | Grant or award | +459 | $10.55 | $4,842 |
| Jan 5, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Option exercise | +20,000 | — | — |
| Jan 5, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Option exercise | +47,668 | — | — |
| Jan 5, 2026 | Moore Paul Andrew Officer (Chief Scientific Officer) | Option exercise | +17,168 | — | — |
| Jan 5, 2026 | Smith Jeffrey T L Officer (EVP & Chief Medical Officer) | Open-market sale | −10,538 | $25.10 | $264,504 |
| Jan 5, 2026 | Kenneth Galbraith Director, Officer (Chair & CEO) | Open-market sale | −22,657 | $25.10 | $568,691 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.